Open Access<p>Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection</p>
Author(s) -
Francis Zamora,
Ellen Dowers,
Faiza Yasin,
Onyema Ogbuagu
Publication year - 2019
Publication title -
hiv/aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 22
ISSN - 1179-1373
DOI - 10.2147/hiv.s216067
Subject(s) - dolutegravir , lamivudine , regimen , medicine , pharmacology , integrase inhibitor , context (archaeology) , drug , human immunodeficiency virus (hiv) , pharmacodynamics , virology , antiretroviral therapy , pharmacokinetics , viral load , virus , chronic hepatitis , biology , paleontology
There have been remarkable advances in drug development for the treatment of HIV-1 infection. From the co-formulation of combination antiretroviral therapy (cART) into single-tablet regimens to the development of long-acting antiretroviral (ARV) drug formulations, the treatment of HIV has and will become much more tolerable and less complicated for patients. In addition, and appropriately, there is a focus on reducing short- and long-term toxicities of treatment while maintaining robust efficacy. One of such approaches includes 2-drug regimen constructs that contain and retain effective ARV compounds while excluding components that have relatively unfavorable toxicity profiles. The first-ever 2-drug regimen approved for the treatment of HIV-1 infection for treatment-naive people living with HIV (PLWH), consisting of the integrase inhibitor dolutegravir (DTG) and the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine (3TC), is reviewed in this paper. The chemical composition and properties, pharmacokinetic and pharmacodynamics profile, and clinical trial data on efficacy and safety of DTG/3TC are presented. An expert opinion aims to highlight important considerations for the use of DTG/3TC in the context of existing and emerging ARV options.